Objectives: Hypermethylation-induced epigenetic silencing of tumour suppressor genes (TSGs) are frequent events during carcinogenesis. MicroRNA-142 (miR-142) is found to be dysregulated in cancer patients to participate into tumour growth, metastasis and angiogenesis. However, the tumour suppressive role of miR-142 and the status of methylation are not fully understood in hepatocellular carcinoma (HCC).
| INTRODUCTION
Primary hepatic malignancy is the second leading causes of cancer-related death worldwide, the majority of which are hepatocellular carcinoma (HCC) with over 5 00 000 new cases diagnosed every year and about 10% of all cancer deaths. Asia and Africa have the highest incidence rates of liver cancer all over the world. 1 Because of the characteristics of HCC that typically late-stage presentation and aggressive nature, there are limited treatment options which lead to the very poor 5-year survival of patients with HCC (less than 40%). Importantly, patients with advanced disease are not eligible for curative hepatectomy or hepatic transplantation, and even for those patients who undergo surgical resection, the high recurrence rate is the main causes for low survival time. 2 The molecular pathogenesis involved into its aggressive nature and high recurrence rate are complicated, thus understanding the potential mechanisms of HCC pathogenesis, including genetic and epigenetic alterations, is crucial to uncover efficient new treatment.
MicroRNAs (miRNAs) are non-coding RNAs of 20-22 bases in
length that regulate gene expression post-transcriptionally via binding to the 3' untranslated regions (UTRs) of mRNAs. 3 Numerous evidences indicated that miRNAs influence numerous cancer-relevant processes such as proliferation, cell cycle, apoptosis, differentiation, metastasis and metabolism. 4 Many miRNAs could function as oncogenes or tumour suppressors during carcinogenesis and their dysregulations in tumours were frequently occurred, including in HCC.
miR-21 was reported to be highly overexpressed in HCC tumours and contributed to HCC growth and spread by modulating the tumour suppressor PTEN expression. 5 miR-29 down-regulation was significantly associated with worse disease-free survival of HCC patients and two anti-apoptotic molecules, Bcl-2 and Mcl-1, as direct targets of miR-29 for the regulation of apoptosis. Epigenetic disorders have been discovered to be associated with many kinds of significant human diseases including cancer. 10 As the first type of epigenetic mark, DNA methylation is the most characterized epigenetic phenomenon, hypermethylation and epigenetic silencing of tumour suppressor genes are frequent events during the development of cancer. In bladder cancer, the tumour suppressor miR-127 was down-regulated and silenced by promoter DNA hypermethylation in tumour tissues. 11 The methylation of promoter CpG islands of miR34a was found in the majority of primary prostate carcinoma samples, which led to the loss expression of miR-34a. 12 However, the correlation between methylation and the loss of miR-142 in HCC is unclear.
In this study, we investigated the function of miR-142 in HCC and its relationship with methylation. We found that miR-142 was down-regulated in HCC tissues and cell lines which contributed to the up-regulation of its direct target transforming growth factor β (TGF-β) to promote tumour growth, metastasis and angiogenesis. The decreased expression of miR-142 attributed to the hypermethylation and the methylation inhibitor 5-Aza could restore the expression of miR-142 to suppress the TGF-β expression and related pro-tumour functions in hepatocellular carcinoma.
| MATERIAL AND METHODS

| Tumour samples
Hepatocellular carcinoma tissues (n = 50) and corresponding relativenormal tissues (n = 50) were collected from Nanfang Hospital 
| Cell lines and reagents
The of TGFB1 was conducted by GenePharma (Shanghai, China).
| RNA isolation and qRT-PCR
After the cells were harvested, PBS was used to wash for three times, total RNA from tissues or HepG-2 and SMMC-7721 cells was ex- Table 1 .
| Western blots
According to the manufacturer's instructions, the whole cell protein extracts were prepared and all proteins were resolved on a 10% SDS denatured polyacrylamide gel and were then transferred onto a nitrocellulose membrane, which were blocked in 5% non-fat milk in TBST buffer (Tris buffer saline containing 0.1% Tween-20) for 1 hour at room temperature, and subsequently incubated with primary antibodies overnight at 4°C. After washing with TBST buffer, the blots were then incubated with HRP-conjugated secondary antibody for 1 hour at room temperature. After washing with TBST buffer, the blots were visualized using the ECL-Plus reagent (Millipore, Billerica, MA). GAPDH was used as the loading control in the Western blotting.
| Cell transfection
The 
| Dual-luciferase assay
To investigate the direct target of miR-142 on the transcription of 
| Flow cytometry assay
After the indicated treatment, the cells were harvested and sus- 
| Transwell assay
For the migration assay, after the indicated treatment, 2 × 10 4
HepG-2, SMMC-7721 cells were cultured in the upper chamber of a non-coated transwell insert. The lower chamber contained 600 μL medium with 10% bovine serum which was used as a chemo-attractant to encourage cell migration. For the invasion assay, the upper chamber of the transwell inserts were coated with 50 μL of 2.0 mg/mL Matrigel, the cells were plated in the upper chamber and incubated for 24 hour and cells that did not migrate or invade were removed using a cotton swab. Using crystal violet staining, the cells were stained and counted under an inverted microscope. Five random views were selected to count the cells and the independent experiments were repeated three times.
| HUVEC tube formation assay
The conditional supernatants of tumour cells were collected. The HUVEC capillary-like tube formation assay was performed on Matrigel (Solarbio). After the Matrigel coagulated, the plate was added with 5 × 10 4 cells/well and equal volume of supernatants. Cells on Matrigel were incubated for 8 hour and five random fields were choose to calculated the tubes length of tube-like capillary by image pro plus software.
| Methylation analysis
To detect the status of methylation of miR-142 in HCC tissues and cells, genomic DNA was extracted and modified with sodium bisulfite (2 μg) using an EpiTect Bisulfite Kit (Qiagen, Hilden, Germany).
Methylation was determined by methylation-specific PCR, and bisulfite sequencing, and details of methods are shown as previously. Whitney U tests were used to compare the two groups, and multiple group comparisons were analysed with one-way ANOVA. P < .05 was considered to be statistically significant. Data were presented as the mean ± standard deviation (SD).
| RESULTS
| Decreased expression of miR-142 correlates to poor clinical outcomes in HCC
To investigate the clinical role of miR-142 in hepatocellular carcinoma, we collected HCC tissues (n = 50) and corresponding non- were used to confirm the miR-142 level in vitro ( Figure 1B) . We found that the miR-142 level was lower in HepG2 and SMMC7721
than that in HL-7702, which was consistent with the clinical finding.
Moreover, the clinicopathological characteristics were collected and its relationships to miR-142 were determined. Patients with lower expression of miR-142 had high stage of TNM and differentiation and had more metastasis ( Figure 1C-E) . These data suggested that miR-142 was down-regulated to be involved into the progression of HCC.
| TGFB1 is a direct target of miR-142 in HCC
Although some genes (eg TGF-β2, HSP70, HMGB1 and smad3) were To conform the directly target relationship, a luciferase reporter vector with full-length 3'-UTR (wild-type or mutant) of TGF-β was transfected into HepG2 and SMMC7721 cells to perform the luciferase reporter assays and the results showed that miR-142 mimics could significantly impair the luciferase activity of wild-type TGF-β-3'UTR, but not the mutant type ( Figure 2H ).
| miR-142 inhibit the progression of HCC via TGF-β
We next investigated the role of miR-142/TGF-β signals in HCC cell lines, the cell vitality, proliferation, EMT and angiogenesis were estimated. After transfection of miR-142 mimics, the cell vitality of two cells were significantly reduced but could be rescued by the overexpression of TGF-β ( Figure 3A ). Considering that miR-142
could impair the cell vitality of tumour cells, the proliferation was also determined by BrdU proliferation assay ( Figure 3B ) and found that miR-142 inhibited the proliferation of HepG2 and SMMC7721 cells and TGF-β could repress miR-142-induced inhibition of proliferation.
Moreover, the effects of miR-142 on the ability of migration and invasion were analysed ( Figure 3C) . Similarly, the results of transwell assay indicated that miR-142 mimics inhibited the migration and invasion of HepG2 and SMMC7721 cells via TGF-β. We further hypothesized that the impacts on metastasis was due to EMT.
Thus, the expression of epithelial-specific marker E-cadherin, and mesenchymal markers N-cadherin, and Vimentin were estimated ( Figure 3D ). We found that miR-142 was able to elevate the expression of E-cadherin but reduce the expression of N-cadherin and Vimentin, which were restored partly by the introduction of TGF-β. These data suggested that miR-142 inhibit the tumour characteristics of HCC via TGF-β.
| The loss expression of miR-142 is attributed to hypermethylation in HCC
To find out the causes of the loss expression of miR-142 in HCC, the status of methylation of miR-142 was analysed in HCC tissues, and HepG2 and SMMC7721 cells. Bisulfite sequencing analysis 
| DISCUSSION
Cancers are far more complex than realized due to the genetically heterogeneity, which involve with the protean miRNA and long and inhibit the expression of TGFβR1 and impair TGF-β-induced growth inhibition in NSCLC cells. 17 Dickman et al. reported that miR-142 in small extracellular vesicles of oral cancer was associated with increased vascular density in vivo. 18 We here found that miR-142 was significantly reduced during the development of HCC and TGF-β could be targeted to inhibit the cell vitality, proliferation, EMT and angiogenesis of HCC cells. Other molecular in TGF-β pathway, eg SMAD3, was also reported to be targeted and inhibited by miR-142. 19 Ma et al. found that miR-142-5p promoted tumour cell proliferation and inhibited apoptosis and play as a negative regulator in TGF-β pathway by targeting SMAD3. 20 These inconsistent researches emphasized the multifunction of miR-142 in distinct cancer environments.
Currently, the mechanisms of regulation of differentially expressed miRNAs in cancer mainly consisted of transcriptional regulation, genetic alterations in miRNA biogenesis pathways and epigenetic mechanisms. 4 Representative examples such as miR-9-1 in breast cancer 21 and miR-124a in colorectal tumours 22 was suppressed by CpG island hypermethylation in tumour tissues when compared to normal controls. Watanabe et al. reported that miR-142 was highly methylated in fibroblasts 23 and other found that mir-142 was epigenetically repressed by DNA methylation in mesenchymal cells, 24 whereas miR-142 was found to be hypomethylated in cutaneous T-cell lymphoma for its up-regulation. 25 But the status of methylation of miR-142 in cancer was unclear. We here demonstrated that the down-regulation of miR-142 was attributed to its hypermethylation in HCC. The methylation inhibitor 5-Aza ), the proliferation and cell vitality was estimated by (A) CCK-8 and (B) BrdU assay. C, The migrations and invasions of two tumour cells were determined by transwell assay. D, The expressions of EMT markers were estimated by WB. E, Different conditional supernatants were collected and the HUVEC capillary-like tube formation assay was performed on Matrigel.*P < .05, **P < .01. Data represent the mean ± SD could restore the expression of miR-142 in HCC cells. Similarly, in osteosarcoma (OS), the hypermethylation of miR-142 was found in OS samples and led to its loss-of-function, which promoted the cell invasion and growth. 26 
| CONCLUSIONS
In summary, we uncovered the hypermethylated status of miR-142 in HCC, which explained the decreased expression of miR-142.
The methylation inhibitor 5-Aza could restore the expression of miR-142 for targeting and inhibiting the TGF-β-dependent tumour proliferation, EMT and the ability of pro-angiogenesis.
